New synthesis of a high molecular weight ligand derived from dota; thermodynamic stability of the MRI contrast agent formed with gadolinium

Contrast Media and Molecular Imaging

Volumn 3, Issue 6, 2008, Pages 243-252

  Pierrard, Jean Claude ^a   Rimbault, Jean ^a   Aplincourt, Michel ^a   Le Greneur, Soizic ^b   Port, Marc ^b  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b Laboratoire Guerbet   (France)

Author keywords

Dota derivative; Gadolinium; MRI contrast agent; Stability constant

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 2 [4,7,10 TRIS (1 TERT BUTOXYCARBONYL 3 CARBOXY PROPYL) 1,4,7,10 TETRAAZACYCLODODEC 1 YL]PENTANEDIOIC ACID 1 TERT BUTYL ESTER; 2 [4,7,10 TRIS (3 BENZYLOXYCARBONYL 1 TERT BUTOXYCARBONYL PROPYL) 1,4,7,10 TETRAAZACYCLODODEC 1 YL]PENTANEDIOIC ACID 5 BENZYLESTER 1 TERT BUTYL ESTER; 2 BROMOPENTANEDIOIC ACID 5 BENZYLESTER; 2 BROMOPENTANEDIOIC ACID 5 BENZYLESTER 1 TERT BUTYL ESTER; CONTRAST MEDIUM; GADOLINIUM; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; DIAGNOSTIC AGENT; LIGAND; SINGLE HETEROCYCLIC RINGS;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL REACTION; CHEMICAL STRUCTURE; COMPLEX FORMATION; LIGAND BINDING; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE IMAGING; PH; PRIORITY JOURNAL; PROTON TRANSPORT; SYNTHESIS; THERMODYNAMICS; THERMOSTABILITY; CHEMISTRY; DRUG STABILITY; METHODOLOGY;

CONTRAST MEDIA; DRUG STABILITY; GADOLINIUM; HETEROCYCLIC COMPOUNDS, 1-RING; LIGANDS; MAGNETIC RESONANCE IMAGING; MOLECULAR WEIGHT; THERMODYNAMICS;

EID: 58749115772     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.258     Document Type: Article

References (41)

1. 3+ complexes with 1,4,7,10-tetra(2-glutaryl)-1,4,7,10 tetraazacyclododecane: EXAFS, luminescence, potentiometric studies, and quantum calculation. Eur. J. Inorg. Chem 2003: 3007-3020.
2. Port M, Rousseaux O, Raynal I, Woods M, Parker D, Moreau J, Rimbault J, Pierrard J-C, Aplincourt M. Synthesis and physicochemical characterization of 1,4,7,10-tetra(2-glutaryl)-1,4,7,10 tetraazacyclododecane lanthanide complexes. Acad. Radiol. 2002; 9 (suppl 2): S300-S303.
3. Port M, Corot C, Rousseaux O, Raynal I, Devoldere L, Idee JM, Dencausse A, Le Greneur S, Simonot C, Meyer D. P792: a rapid clearance blood pool agent for magnetic resonance imaging preliminary results. Magn. Reson. Mater. Phys., Biol. Med. 2001; 12: 121-127.
4. Port M, Corot C, Raynal I, Idee JM, Dencausse A, Lancelot E, Meyer D, Bonnemain B, Lautrou J. Physicochemical and biological evaluation of P792, A. rapid-clearance blood-pool agent for magnetic resonance imaging. Invest. Radiol. 2001; 36(8): 445-454.
5. Turetschek K, Floyds E, Shames DM, Roberts TPL, Preda A, Novikov V, Corot C, Carter WO, Brasch RC. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology. Magn. Reson. Med. 2001; 45(5): 880-886.
6. Bourrasset F, Dencausse A, Bourrinet P, Ducret M, Corot C. Comparison of plasma and peritoneal concentrations of various categories of MRI blood pool agents in a murine experimental pharmacokinetic model. Magn. Reson. Mater. Phys., Biol. Med. 2001; 12: 82-87.
7. Pradel C, Siauve N, Bruneteau G, Clement O, De Bazelaire C, Frouin F, Wedge SR, Tessier JL, Robert PH, Frija G, Cuenod CA. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor. D4190: an in vivo assessment using dynamic MR imaging and macromolecula contrast media. Magn. Reson. Imag. 2003; 21: 845-851.
8. Van Der Elst L, Raynal Y, Port M, Tisnes P, Muller RN. In vitro relaxometric and luminescence characterization of P792 (gadomelitol, vistarem), an efficient and rapid clearance blood pool MRI contrast agent. Eur. J. Inorg. Chem. 2005; 6: 1142-1148.
9. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fund. Clin. Pharmacol. 2006: 563-576.
10. Thomsen HS, Morcos SK. Nephrogenic systemic fibrosis and noionic linear chelates. Am. J. Roentgenol. 2007; 188(6): W580.
11. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agent: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br. J. Radiol. 2007; 80(950): 73-76.
12. Bongartz G. Imaging in the time of NDF/NSF: do we have to change our routines concerning renal insufficiency? Magn. Reson. Mater. Phys. 2007; 20(2): 57-62.
13. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin. J. Am. Soc. Nephrol. 2007; 2: 200-202.
14. 3+ with 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (dota)-characterization of the three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS. Chem. Eur. J. 2004; 10(20): 5218-5232.
15. 5do3ap and similar dota-like ligands. Polyhedron 2007; 26: 4119-4130.
16. Wang XW, Jin T, Comblin V, Lopez-Mut A, Merciny E, Desreux JF. A Kinetic Investigation of the lanthanide DOTA chelates. stability and rates of formation and dissociation of a macrocyclic gadolinium(III) polyaza polycarboxylic MRI contrast agent. Inorg. Chem. 1992; 31: 1095-1099.
17. 2+ complexes of macrocyclic polyamino carboxylates. Inorg. Chem 1995; 34: 6472-6480.
18. Toth E, Kiraly R, Platzec J, Brücher E. Equilibrium and kinetic studies on complexes of 10-[2,3-dihydroxy-(1-hydroxymethyl)-propyl]-1,4,7,10-tetraazacyclodecane- 1,4,7-triacetate. Inorg. Chim. Acta 1996; 249: 191-199.
19. Toth E, Brücher E, Lazar I, Toth I. Kinetics of formation and dissociation of lanthanide(III)-DOTA complexes. Inorg. Chem 1994; 33: 4070-4076.
20. Eisenwiener KP, Powell P, Mäecke HR. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg. Med. Chem. Lett 2000; 10: 2133-2135.
21. Armstrong A, Brackenridge I, Jackson RFW, Kirk Jm. A new method for the preparation of tertiary butyl ethers and esters. Tetrahedron Lett. 1988; 29: 2483-2486.
22. Chandrasekaran S, Kluge AF, Edwards JA. Synthesis of substituted b-lactams by addition of nitromethane to 6-oxopenicillates and 7-oxocephalosporanates. J. Org. Chem. 1977; 42: 3972-3973.
23. Carriera EM, Du Bois JJ. (+)-Zaragozic acid C: synthesis and related studies. J. Am. Chem. Soc. 1995; 117: 8106-8125.
24. Bryan DB, Hall RF, Holden KG, Huffman WF, Gleason JG. Nuclear analogs of beta-lactam antibiotics. 2. The total synthesis of 8-oxo-4-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acids. J. Am. Chem. Soc. 1977; 99: 2353-2355.
25. Pearson DA, Blanchette M, Baker ML, Guindon CA. Trialkylsilanes as scavengers for the trifluoroacetic acid deblocking of protecting groups in peptide synthesis. Tetrahedron Lett. 1989; 30(21): 2739-2742.
26. Metha A, Jaouhari R, Benson TJ, Douglas KT. Improved efficiency and selectivity in peptide synthesis: use of triethylsilane as a carbocation scavenger in deprotection of t-butyl ester and t-butoxycarbonyl-protected sites. Tetrahedron Lett. 1992; 33(37): 5441-5444.
27. Fournaise R, Petitfaux C. Etude de la formation des complexes en solution aqueuse - III. Nouvelle méthode d'affinement des constantes de stabilité des complexes et des autres paramètres des titrages protométriques. Talanta 1987; 34: 385-395.
28. Stockelmann G, Kettrup A, Specker H. Z. Stabilitätskonstanten der Kupfekomplexe von Acetessigsäureamiden. I Anorg. Allg. Chem. 1970; 372: 134-144.
29. Desreux JF, Merciny E, Loncin MF. Nuclear magnetic resonance and potentiometric studies of the protonation scheme of two tetraaza tetraacetic macrocycles. Inorg. Chem 1981; 20: 987-991.
30. 3+ complexes with functionalized macrocyclic ligands based upon 1,4,7,10-tetraazacyclododecane. J. Chem. Soc., Dalton Trans. 2000; 697-705.
31. Delgado R, Da Silva FJ Jr. Metal complexes of cyclic tetraazatetra-acetic acids. Talanta 1982; 29: 815-822.
32. Bruce JI, Dickins RS, Govenlock LJ, Gunnlaugsson T, Lopinski S, Lowe MP, Parker D, Peack RD, Perry JJ, Aime S, Botta M. The selectivity of reversible oxy-anion binding in aqueous solution at a chiral europium and terbium center: signaling of carbonate chelation by changes in the form and circular polarization of luminescence emission. J. Am. Chem. Soc. 2000; 122: 9674-9684.
33. Aime S, Barge A, Bruce JI, Botta M, Howard JAK, Moloney JM, Parker D, De Sousa AS, Woods M. NMR, relaxometric, and structural studies of the hydration and exchange dynamics of cationic lanthanide complexes of macrocyclic tetraamide ligands. J. Am. Chem. Soc. 1999; 5762-5771.
34. Lowe MP, Parker D. Controlable pH modulation of lanthanide luminescence by intramolecular switching of the hydration state. Chem. Commun. 2000; 707-708.
35. 1H relaxation effects of ternary complexes formed between Gd-DTPA, Gd-DTPA-BMA, Gd-DOTA, and Gd-EDTA and citrate, phosphate, and carbonates ions. Magn. Reson. Med. 1997; 38: 146-150.
36. Howard JAK, Kenwright AM, Moloney JM, Parker D, Port M, Navet M, Rousseau O, Woods M. Structure and dynamics of all of the stereoisomers of europium complexes of tetra(carboxyethyl) derivatives of DOTA: ring inversion is decoupled from cooperative arm rotation in the RRRR and RRRS isomers. Chem. Commun. 1998; 1381-1382.
37. Smith RM, Martell AE. Critically selected stability constants of metal complexes. Database. Gaithersburg, 1995; version 2p.
38. 4 as an ionic medium. Bull. Chem. Soc. Jpn 1973; 46: 1720-1723.
39. Din Ngo N, Burkov KA. State of gadolinium ions in aqueous solution. Russ. J. Inorg. Chem. 1974; 19(5): 680-681.
40. Hermann PH, Kotek J, Kubicek V, Lukes I. Gadolinium(III) complexes as MRI contrast agents: ligand desing and properties of the complexes. Dalton Trans. 2008; 23: 3027-3047.
41. Clarke ET, Martell AE. Stabilities of the alkaline earth and divalent transition metal complexes of the tetraazamacrocyclic tetraacetic acid ligands. Inorg. Chim. Acta 1991; 190: 28-36.